市场业绩承压，GE医疗回应出售中国业务股份传闻｜快讯

Core Viewpoint - GE Healthcare is reportedly exploring options to sell its stake in the Chinese market due to declining revenues, rising tariff costs, and increasing competition from local players [2][3] Financial Performance - GE Healthcare's global revenue for the year ending December 31, 2024, was $19.7 billion, a slight increase of 1% year-on-year [2] - The revenue from the Chinese market for GE Healthcare was $2.36 billion, representing a significant decline of 15% year-on-year, marking the largest drop since the company became independent in 2023 [2] - In the first half of 2025, GE Healthcare reported a further 3% decline in revenue from the Chinese market [3] Market Comparison - In the first half of 2025, Siemens Healthineers achieved revenue of €11.571 billion (approximately $13.39 billion), a year-on-year increase of 7% [3] - GE Healthcare's revenue for the same period was $9.78 billion, reflecting a 3% year-on-year growth [3] - Philips Healthcare reported revenue of €8.174 billion (approximately $9.46 billion), showing a year-on-year decline of 1.77% [3] - Siemens Healthineers was the only major player to experience growth in the Chinese market, with a 2.4% increase, while GE Healthcare and Philips saw declines of 2% and 11%, respectively [3]